Encube Ethicals founder Mehul Shah has purchased a luxury apartment in Mumbai for Rs 106.52 crore, just days before the company filed its draft papers for a Rs 3,000 crore IPO. The proposed public offer is an entirely Offer for Sale (OFS), meaning the company will not receive any fresh capital from the issue. Investors should note this structure as the promoter and existing shareholders look to monetize their holdings.
Mehul Shah, the founder of Encube Ethicals, has acquired a luxury apartment in Mumbai’s Juhu neighborhood for Rs 106.52 crore. The transaction, registered on July 31, 2026, took place shortly before the pharmaceutical firm filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) on August 1, 2026. The property, located in the Lodha Avalon project, spans over 9,800 square feet and includes five dedicated parking spaces.
IPO Structure and Investor Context
The most significant detail for potential investors regarding the upcoming Rs 3,000 crore IPO is its structure. The issue is a 100% Offer for Sale (OFS), meaning that all shares being sold belong to the existing promoters and investors—specifically, Mehul Shah and Frontier Investment Holdings Pte. Ltd. Consequently, the company will not receive any of the proceeds from the IPO to fund its business operations or future expansion. Investors participating in the IPO will be purchasing equity directly from the current shareholders rather than providing capital for the company's growth.
Financial Performance and Business Model
Encube Ethicals operates primarily in the topical pharmaceutical formulations sector, serving as a contract development and manufacturing organization (CDMO) for various global healthcare companies. As of March 31, 2026, the company reported a strong financial performance for the fiscal year, with revenue reaching Rs 1,848.7 crore and a net profit of Rs 436.7 crore. The firm maintains healthy profitability, with an EBITDA margin of 35.88% and a net profit margin of 23.62%. Additionally, the company has managed its balance sheet effectively, with a debt-to-equity ratio of 0.13, indicating low reliance on borrowings.
Operational Risks and Market Focus
While the company’s financial health appears robust, investors should consider the specific risks inherent in its business model. Encube Ethicals generates a significant portion of its revenue from international markets, which exposes it to global economic conditions and currency fluctuations. Furthermore, its operations as a CDMO mean it works with over 160 pharmaceutical firms; reliance on these long-term partnerships is critical for consistent revenue. Like many pharmaceutical players, the company is also subject to rigorous oversight by international health authorities, including the USFDA, EU GMP, and Japan PMDA. Any compliance issues or delays in product approvals from these regulators could directly affect the company's ability to supply to its global customers.
Moving forward, the primary monitorables for investors will be the IPO valuation set by the promoters, the response from institutional investors, and the company's ability to maintain its profit margins while navigating global regulatory environments. The lack of fresh capital infusion into the business means that the company’s future growth will likely continue to rely on its existing cash flow and business strategies.